Skip to main content
Eupraxia Pharmaceuticals Inc. logo

Eupraxia Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · EPRX ISIN · CA29842P1053 TSX Manufacturing
Open in API
Filings indexed 226 across all filing types
Latest filing 2025-11-04 Interim / Quarterly Rep…
Country CA Canada
Listing TSX EPRX

About Eupraxia Pharmaceuticals Inc.

https://eupraxiapharma.com/

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing targeted, extended-release therapies using its proprietary drug delivery platform, Diffusphere™. This technology is engineered to optimize local, controlled drug delivery directly to diseased tissues, aiming to maximize efficacy and minimize systemic side effects. Eupraxia addresses therapeutic areas with significant unmet medical needs, particularly in gastrointestinal and musculoskeletal diseases. The company's lead product candidate, EP-104GI, is currently in Phase 2 clinical trials for the treatment of Eosinophilic Esophagitis (EoE), a chronic inflammatory disease of the esophagus. The Diffusphere platform is designed to potentially offer long-term relief with fewer doses across various conditions, including inflammatory diseases, oncology, and pain.

Recent filings

Filing Released Lang Actions
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 1% confidence The document contains comprehensive consolidated financial statements, including balance sheets, statements of operations, statements of shareholders' equity, and statements of cash flows for the three and nine months ended September 30, 2025. It also includes detailed notes to the financial statements. This structure is characteristic of an interim quarterly report, not an announcement or a summary. 9M 2025
2025-11-04 English
Interim MD&A - English.pdf
Management Reports Classification · 1% confidence The document is titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” for the three and nine months ended September 30, 2025. It consists of MD&A commentary—management’s detailed explanation of financial results, business trends, outlook, forward-looking statements, and risk factors—without the full financial statements. This aligns precisely with the definition of a Management Report (MDA).
2025-11-04 English
52-109F2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a Form 52-109F2 Certificate of Interim Filings signed by the CFO, certifying interim financial statements and MD&A for the period ended September 30, 2025 under Canadian securities rules. It is not the full interim report or an announcement of report publication but a regulatory certification. It best fits the general Regulatory Filings fallback category (RNS).
2025-11-04 English
52-109F2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a Form 52-109F2 Certification of Interim Filings (a statutory certificate under Canadian NI 52-109) by the CEO, which is not itself the interim report or MD&A, nor an earnings release or management discussion. It is a compliance/certification form required by securities legislation. It does not present financial results or detailed MD&A, but is a regulatory filing. Therefore it falls under the fallback category for miscellaneous regulatory filings (RNS).
2025-11-04 English
News release - English.pdf
Earnings Release Classification · 1% confidence The document is a press release announcing Eupraxia Pharmaceuticals’ third quarter 2025 financial results, with bullet-point highlights, net loss, cash runway, trial updates, financing summary, and forward-looking statements. It is an initial earnings announcement rather than a full interim report or regulatory filing. This aligns precisely with the definition of an Earnings Release (ER). Q3 2025
2025-11-04 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing clinical trial data, operational updates on the RESOLVE trial, and development plans for the EP-104GI program, along with a mention of recent financing and a webinar. It is not an annual or quarterly report, earnings release, management change notice, regulatory audit, or financing terms announcement. It does not attach or publish a report itself but rather provides an operational update. Therefore, it falls into the fallback category for miscellaneous regulatory announcements.
2025-09-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.